A few recent videos on Eyetube which I thought were worth starting a new thread in relation to. These videos not only highlight the high efficacy of iTrack Advance, but also the fact that it is a procedure that is really in a class of its own. It does not need to compete with other MIGS devices, it complements them incredibly well and is also incredibly effective on a standalone basis. Flush out the drainage system, then insert any stents or other devices! Or just flush it out for patients that may be hesitant to tear or have a device implanted in their eye. Either way, it's a procedure that really does work for all types of patients and makes so much sense as a method of early intervention.
In relation to efficacy, these videos are similar to other videos shared here in that unlike other MIGS devices, with iTrack Advance you can actually see the positive effect it is immediately having with your own eyes (ie the OVD flushing out and clearing the drainage system). The company doesn't need sales reps to go around telling doctors how effective iTrack Advance is, the doctors can see it for themselves just by watching a video of a procedure!
More importantly though, these videos show Dr Paul Singh (one of the most influential ophthalmologists in the world - voted number 19 on the power list - and a strong advocate of canaloplasty) combining it with all the major stent-based procedures developled by Glaukos and Alcon. This is incredibly exciting, other MIGS cannot really be combined with each other, but iTrack Advance is unique in that it is the only device really that enables this. By simply flushing out the canal, it allows for additional procedures to be performed at the same time or later on down the track. The approach of clearing out the canal and putting in a stent device, as well as often cataract surgery, is popular as well. Patients see it as a "belt and braces" approach. It reassures them that they have the best chance of avoiding vision loss due to their glaucoma, and often allows for them to go on to live a normal life free of the burden of drops.
This is obviously great from a patient's perspective; they get to leave feeling the closest they probably could to being free of glaucoma. But why is this so important from a business perspective? A number of reasons, the fact that this can be combined with stents avoids the need for Nova Eye to actually compete with these larger players. If anything, Nova Eye will benefit significantly from these companies expanding and growing, as that means more procedures to combine iTrack Advance with. EYE is literally benefiting from the massive marketing spend of the larger players! This also proves that there are enormous synergy benefits for these larger players, if they were to acquire EYE. Clearing the canal prior to inserting a stent is clearly popular, it would make sense for either Alcon or Glaukos to acquire EYE and potentially even make iTrack Advance exclusive for their procedure, as a way of differentiating from other stents. Alcon originally acquired its Hydrus device for well over $700m AUD in 2022, so Nova Eye Medical would look like an absolute steal at current prices.
Even more excited for the full year results now! I'm guessing the larger players will be looking closely at them as well to assess possible M&A options.
iTrack Advance With iStent Infinite for Mild POAG - EyetubeCombination MIGS: iTrack Advance With iStent Infinite - EyetubeiTrack Advance and Hydrus Microstent - EyetubeObviously much more that differentiates iTrack Advance and makes it so special, so it would be great to see this thread being the dedicated location for all the evidence we manage to find that highlights this! Knowing there is a strong moat and the product is significantly differentiated from peers is obviously a very important criteria for any investor.
(20min delay)